Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, shares how the company is ...

Accelerated approval was based on results from the Phase I/II LINKER-MM1 trial, which showed a 70% objective response rate in ...

Results from the Phase III ZENITH trial show that patients treated with Winrevair (sotatercept-csrk) for pulmonary arterial ...

Lunit and Microsoft are working together to push for the use of AI in cancer diagnosis. Lunit and Microsoft are working ...

Expert panelists emphasize the importance of trusted data sources, strong payer partnerships, economic incentives, and ...

It’s the caliber of leadership that brings teams together, demands accountability, and drives purposeful, decisive action.

What’s impacting medical affairs today is the update to drug approvals: there’s more visibility, more scrutiny, and more ...